J. Weisinger

Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry

Z. Borbényi, Gábor Szalóki, Á. Czeti, 2022, Pathology & Oncology Research.

Detection of emerging ibrutinib resistance by flow cytometry in patients with chronic lymphocytic leukemia

Z. Borbényi, Gábor Szalóki, Á. Czeti, 2021 .

Screening and monitoring of the BTKC481S mutation in a real‐world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy

P. Csermely, L. Gergely, E. Sebestyén, 2021, British journal of haematology.

What are the bone lesions in patients with more than four years of a functioning renal transplant?

R. Carlini, E. Bellorín-Font, E. Rojas, 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax

R. Szász, D. Alpár, Z. Pauker, 2023, International journal of molecular sciences.

Low‐burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation

D. Alpár, Z. Pauker, Á. Bátai, 2023, The journal of pathology. Clinical research.

Screening and monitoring of the BTK C481S mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy

P. Csermely, L. Gergely, R. Szász, 2021 .